Peptides like BPC-157: promising science, thin evidence, real risks
September 27, 2026 · 20 min read
Several discussions of peptide therapeutics cover compounds like BPC-157, TB-500 and growth-hormone-releasing peptides. They describe exciting early data on healing and metabolism alongside limited human trials and sourcing risks. Readers tempted by peptide hype need that balance before experimenting.
The rules, numbers and steps worth keeping in front of you.
- Peptides are potent, early-stage drugs, not harmless supplements.
- Koniver: thousands of his patients became less stiff and sore on BPC-157.
- Koniver's evidence is clinical observation, not published trials.
- Huberman: almost all the data come from rats and mice; he knows of one poor human study.
- Huberman: BPC-157 grows new blood vessels, so it is a potential tumor growth risk.
- Huberman: be very cautious with a known cancer, tumor concerns, or eye disease involving vascular overgrowth.
- Never use products labeled for research purposes only; contamination and anaphylaxis are risks.
- Koniver caps ipamorelin-type peptides at 100 micrograms.
- Cycle off: Koniver uses five days on, two off; Huberman suggests about eight weeks on, then eight to ten off.
- Huberman: some growth hormone peptides raise prolactin and cortisol.
- Huberman would avoid CJC-1295 until its safety question is resolved.
- Since October 2023 the FDA has barred compounding of BPC-157.
- Huberman: sleep, exercise and not eating before bed can raise growth hormone without injections.
- Use peptides only with a board-certified physician experienced in them.
This is the short form. The full insight has every expert's reasoning, their own words and the sources.